Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 5.
AMINOSYN 5% vs AMINOSYN II 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 5% provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair in patients unable to tolerate oral intake.
Aminosyn II 5% provides essential and non-essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair. It supports metabolic processes in patients unable to maintain adequate nutrition enterally.
Intravenous infusion; 500 mL of 5% solution (25 g protein equivalent) per day, typically at a rate not exceeding 100 mL/hour. Dosage individualized based on protein requirements and metabolic status.
Intravenous infusion via central line, initial rate 50 mL/hour, increase by 25 mL/hour every 24 hours to goal rate of 1-2 mL/kg/hour (maximum 125 mL/hour). Total daily dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 30-40 mL/kg/day).
None Documented
None Documented
Not applicable as a drug; amino acids have rapid turnover with half-lives varying from minutes to hours depending on the individual amino acid.
Not applicable as a single entity; individual amino acids have variable half-lives (e.g., 10-30 min for most), reflecting rapid distribution and metabolism. Clinical context: continuous infusion maintains steady state.
Amino acids are metabolized; nitrogen is excreted renally as urea (80-90%) and in feces (5-10%).
Renal elimination of amino acids is minimal under normal conditions; excess amino acids are metabolized, and nitrogen is excreted as urea (renal, ~80-90%) and ammonia. Biliary/fecal excretion negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution